

Emily J. Martin<sup>1</sup>, Eden Brauer<sup>1</sup>, Shelby D. Yaceczko<sup>1</sup>, Katie Pool<sup>1</sup>, Vanessa Rubalcava<sup>1</sup>, Janette Villa<sup>1</sup>, Debbie Moran<sup>1</sup>, Carrie Tompkins Stricker<sup>2</sup>, Christina Sigler<sup>3</sup>, Kristen Dinunno<sup>3</sup>, Nadia Still<sup>3</sup>, Debra Wujcik<sup>3</sup>, Timothy R. Donahue<sup>1</sup>

<sup>1</sup>University of California Los Angeles, Los Angeles, CA; <sup>2</sup>Canopy Cancer Collective, Narberth, PA; <sup>3</sup>Carevive by Health Catalyst, South Jordan, UT

## Background

- Electronic patient-reported outcomes (ePROs) are part of high-quality pancreatic cancer care, but obstacles exist to implementation at scale to inform care across a complex health system.
- As part of the Canopy Cancer Collective initiative, the UCLA Agi Hirshberg Center for Pancreatic Diseases implemented a navigator facilitated model of ePRO-informed pancreatic cancer care.
- This study aimed to determine the feasibility of implementing ePROs using Carevive's remote symptom monitoring (RSM) platform.

## Methods

- Patients with pancreatic ductal adenocarcinoma (PDAC) receiving ongoing care at the center submitted baseline ePROs and were invited to enroll in the RSM program, PROMpt®, from January to November 2025.
- Baseline surveys captured symptom burden using NCI PRO-CTCAE items and health-related quality of life (HRQoL) using EORTC QLQ-C30.
- In August, the team added a recurring Pancreatic Supplement Survey (PSS) distributed every 2 months to enrolled patients, which incorporated three instruments: Feeling Heard and Understood, Pancreatic Exocrine Insufficiency, and the Malnutrition Screening Tool (MST).
- A positive MST screen of  $\geq 2$  triggered an alert, which was directly sent to the navigator for review.


## Conclusions

- Routine collection of ePROs in a PDAC population facilitated by patient navigation is feasible.
- Symptom burden, HRQoL concerns, and nutritional needs were identified.
- Next steps include measuring impact on patient experience and clinical outcomes of interest.

## Results

- During implementation, 62 of 88 eligible patients (70%) submitted a baseline survey; of these, 46 (74%) enrolled in PROMpt® for ongoing monitoring.
- According to baseline data, the most prevalent symptoms reported by patients were fatigue, decreased appetite, anxiety, insomnia, and numbness/tingling.
- Most patients reported moderate-to-high HRQoL.
- Since the PSS roll-out, 19 patients submitted 28 recurring assessments. All patients reported feeling heard and understood by the care team, approximately half were taking pancreatic enzymes, and 11 MST alerts were triggered with navigator response.

### Results: Symptom Burden & HRQoL at Baseline



### Results: Recurring Pancreatic Supplement Survey

Distributed every 2 months

